Lüdeke I, Terheyden P, Grisanti S, Lüke M
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Schleswig Holstein, Campus Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Deutschland.
Hautkrebszentrum Lübeck, Klinik für Dermatologie, Allergologie und Venerologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Deutschland.
Ophthalmologe. 2016 Oct;113(10):861-863. doi: 10.1007/s00347-016-0226-8.
Inhibitors of the mitogen-activated protein kinase (MAPK) signal pathway have decisively improved the prognosis of metastatic cutaneous melanoma in patients with an activating mutation in position V600 of the BRAF gene. We report on a patient who was regularly examined in our clinic while participating in a randomized blinded clinical trial. The aim of this trial was to examine the effectiveness and tolerability of a combination of the BRAF inhibitor dabrafenib and the MAPK kinase (MEK) inhibitor trametinib compared with a monotherapy with dabrafenib (plus placebo). During therapy the patient developed a diffuse neuroretinal detachment which could not be completely reversed after discontinuation of the study medication.
丝裂原活化蛋白激酶（MAPK）信号通路抑制剂已显著改善了BRAF基因V600位点激活突变的转移性皮肤黑色素瘤患者的预后。我们报告了一名在参与一项随机双盲临床试验期间在我们诊所定期接受检查的患者。该试验的目的是研究BRAF抑制剂达拉非尼与丝裂原活化蛋白激酶（MEK）抑制剂曲美替尼联合使用与达拉非尼单药治疗（加安慰剂）相比的有效性和耐受性。治疗期间，该患者出现了弥漫性视网膜神经脱离，在停用研究药物后未能完全逆转。
